- Design
- Nationwide register-based cohort with weighted cumulative exposure modelling
- Population
- 3749 people with newly diagnosed SLE in Sweden, 2006–2022
- Primary outcome
- First organ damage
- Effect
- 5 mg/day average over 2 years: HR 1.42 (95% CI 1.31 to 1.53)
This nationwide Swedish cohort linked national registers to follow 3749 people with newly diagnosed systemic lupus erythematosus (82% women, median age 48) from 2006 to January 2024. Oral glucocorticoid exposure was measured from pharmacy dispensing, and weighted cumulative exposure models tested which time window of dosing best explained the risk of first organ damage.
Dosing over the previous two years best captured the risk: an average of 5 mg/day was associated with a hazard ratio of 1.42 (95% CI 1.31 to 1.53) for first organ damage. The previous year alone captured it fairly well (HR 1.34, 1.23 to 1.42). For cardiovascular damage, dosing across the previous three years contributed substantially.
This supports current guidance to taper glucocorticoids to 5 mg/day or less of prednisolone equivalent and to stop where possible. It also suggests the harm of a dose accumulates and lingers, so a recent taper does not erase the risk built up before it. As an observational study, it cannot fully separate the effect of steroids from that of the active disease they were treating. Long-term low-dose prednisolone remains common in lupus care in India, which makes steroid-sparing strategies and hydroxychloroquine adherence especially relevant.
- Taper oral glucocorticoids to 5 mg/day or less of prednisolone equivalent, and aim to stop where disease control allows.
- Add or optimise steroid-sparing agents early rather than holding patients on low-dose steroids indefinitely.
- Review cumulative glucocorticoid exposure over the past two to three years at each assessment, not just the current dose.
- Screen for cardiovascular risk factors in patients with significant past steroid exposure.
- Check hydroxychloroquine adherence, which supports steroid tapering.
Why it matters
It challenges the idea that a low maintenance dose is harmless and shows the risk carries forward after the dose is reduced.
Don't overread it
An observational register study cannot fully separate steroid harm from the effect of active lupus.
The statistics, in plain English
A hazard ratio of 1.42 means about 42% higher risk of first organ damage for an average of 5 mg/day over two years, compared with none. The narrow interval reflects the large sample, not proof of causation: sicker patients receive more steroids, and adjustment for disease activity in registers is limited.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free